6,300 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Purchased by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the fourth quarter, Holdings Channel reports. The fund bought 6,300 shares of the company’s stock, valued at approximately $2,093,000.

Several other large investors have also modified their holdings of MEDP. R Squared Ltd bought a new position in shares of Medpace during the fourth quarter valued at approximately $30,000. SBI Securities Co. Ltd. purchased a new stake in Medpace during the fourth quarter worth $31,000. Jones Financial Companies Lllp boosted its position in Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock valued at $38,000 after acquiring an additional 110 shares in the last quarter. Lindbrook Capital LLC increased its holdings in shares of Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after acquiring an additional 29 shares during the period. Finally, True Wealth Design LLC raised its position in shares of Medpace by 16,800.0% in the 3rd quarter. True Wealth Design LLC now owns 169 shares of the company’s stock worth $56,000 after acquiring an additional 168 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Trading Down 0.3 %

NASDAQ:MEDP opened at $316.61 on Friday. The firm has a fifty day simple moving average of $336.40 and a 200-day simple moving average of $339.26. Medpace Holdings, Inc. has a 12 month low of $302.01 and a 12 month high of $459.77. The company has a market capitalization of $9.65 billion, a P/E ratio of 25.07, a PEG ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Equities analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on MEDP shares. Robert W. Baird lifted their target price on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Leerink Partners initiated coverage on shares of Medpace in a research report on Monday. They issued a “market perform” rating and a $330.00 price objective on the stock. Finally, Leerink Partnrs raised shares of Medpace to a “hold” rating in a research report on Monday. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $376.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.